Companies: 10,795·Total market cap: $144.5T
Galectin Therapeutics Inc.

Galectin Therapeutics Inc.

GALTNASDAQHealthcare● Active
$2.40
+$0.07(+3.00%)
Market Cap$158056555
P/E Ratio—
52W High$7.13
52W Low$1.27
SEC Filings

Galectin Therapeutics Inc. (GALT) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001133416 · GALT · NASDAQ · as of Jun 8, 2026

Filing snapshot

1,001+
Total Filings
4
Latest Form
2026-05-28
Most Recent
2002
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001133416 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-31
Fiscal Year End
Mar 31, 2026
Accession No.
0001140361-26-012155
Primary Document
ef20060823_10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001133416 · Accession 0001140361-26-012155

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-15Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-15
View
EFFECTEFFECT
EFFECT
2026-04-10
View
CORRESPCORRESP
CORRESP
2026-04-08
View
UPLOADUPLOAD
UPLOAD
2026-04-06
View
S-3Shelf Registration
S-3
2026-03-31
View
8-KCurrent Report
8-K
2026-03-31
View
10-KAnnual Report
10-K
2026-03-31
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-03-17
View
8-KCurrent Report
8-K
2026-03-17
View
8-KCurrent Report
8-K
2026-01-21
View
8-KCurrent Report
8-K
2026-01-12
View
8-KCurrent Report
8-K
2025-12-19
View
8-KCurrent Report
8-K
2025-12-08
View
8-KCurrent Report
8-K
2025-12-03
View
Showing 1–15 of 456 filingsForm 4 / 144 hidden· 1001 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001133416  |  Exchange: NASDAQ · Healthcare

Galectin Therapeutics Inc. (NASDAQ: GALT) has submitted 1,001+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2002. As a Healthcare sector company with CIK 0001133416, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Galectin Therapeutics Inc.'s most comprehensive regulatory disclosure. The most recent Galectin Therapeutics Inc. 10-K was filed on 2026-03-31 for fiscal year ending 2026. Historical GALT 10-K annual reports are available from 2011 through 2026.

Investors researching Galectin Therapeutics Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
DRTS SEC Filings →LBRX SEC Filings →DSGN SEC Filings →AURA SEC Filings →DMAC SEC Filings →RCKT SEC Filings →ALT SEC Filings →IMAB SEC Filings →
→ GALT Financials→ GALT Earnings→ GALT Insider Trades

Frequently Asked Questions

GALT SEC Filings · 8 questions

Galectin Therapeutics Inc. (GALT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,001+ filings and access original documents at no cost. Galectin Therapeutics Inc.'s CIK is 0001133416.

GALT SEC filingsGalectin Therapeutics Inc. SEC documentsfind GALT 10-K